Advertisement

Topics

Shield's Feraccru likely to command 'high market share and branded pricing'

11:17 EDT 10 May 2019 | Proactive Investors

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru.

The drug's approved and marketed in Europe, with a US approval decision pending for July 27.

Feraccru is an oral product absorbed in the gut. It's also an alternative for those unable to tolerate or unresponsive to first-line salt-based oral iron products.

Original Article: Shield's Feraccru likely to command 'high market share and branded pricing'

NEXT ARTICLE

More From BioPortfolio on "Shield's Feraccru likely to command 'high market share and branded pricing'"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...